225 related articles for article (PubMed ID: 35396660)
1. Incidence of venous thromboembolism and discriminating capacity of Khorana score in lung cancer patients treated with immune checkpoint inhibitors.
Alma S; Eloi D; Léa V; Julie C; Valérie M; Pierre G; Hilgers W; Philippe G; Christine Z; Philippe D
J Thromb Thrombolysis; 2022 Aug; 54(2):287-294. PubMed ID: 35396660
[TBL] [Abstract][Full Text] [Related]
2. Venous thromboembolism incidence and risk assessment in lung cancer patients treated with immune checkpoint inhibitors.
Icht O; Darzi N; Shimony S; Jacobi O; Reinhorn D; Landman Y; Mutai R; Averbuch I; Shochat T; Spectre G; Raanani P; Rotem O; Dudnik E; Peled N; Zer A; Leader A
J Thromb Haemost; 2021 May; 19(5):1250-1258. PubMed ID: 33605020
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the effect of immune checkpoint inhibitors on venous thromboembolism in non-small cell lung cancer patients.
He X; Wei SN; Qin WW; Geng N; Li B; Song S; Wang P
Expert Rev Hematol; 2023; 16(12):1135-1142. PubMed ID: 37883026
[TBL] [Abstract][Full Text] [Related]
4. The value of performance status in predicting venous thromboembolism in lung cancer patients treated with immune checkpoint inhibitors.
Zhang J; Yang L; Tian H; Xu R; Liu D
Eur J Oncol Nurs; 2024 Apr; 69():102527. PubMed ID: 38377652
[TBL] [Abstract][Full Text] [Related]
5. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
6. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy.
Hill H; Robinson M; Lu L; Slaughter D; Amin A; Mileham K; Patel JN
Thromb Res; 2021 Dec; 208():71-78. PubMed ID: 34742139
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact and risk factors of cancer-associated thrombosis events in stage-IV cancer patients treated with immune checkpoint inhibitors.
Kewan T; Ko T; Flores M; Sallam Y; Haddad A; Daw H
Eur J Haematol; 2021 May; 106(5):682-688. PubMed ID: 33565130
[TBL] [Abstract][Full Text] [Related]
8. Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.
Khorana AA; Palaia J; Rosenblatt L; Pisupati R; Huang N; Nguyen C; Barron J; Gallagher K; Bond TC
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36657815
[TBL] [Abstract][Full Text] [Related]
9. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: A Danish cohort study.
Overvad TF; Skjøth F; Piazza G; Noble S; Ording AG; Larsen TB; Nielsen PB
J Thromb Haemost; 2022 Dec; 20(12):2921-2929. PubMed ID: 36112135
[TBL] [Abstract][Full Text] [Related]
10. COMPASS-CAT versus Khorana risk assessment model for predicting venous thromboembolic events in patients with non-small cell lung cancer on active treatment with chemotherapy and/or immunotherapy, the CK-RAM study.
Abdel-Razeq H; Sharaf B; Al-Jaghbeer MJ; Abu-Fares H; Bater R; Shaer MA; Abu-Jaish H; Laban DA; Salamah O; Tamimi F; Ashouri K; Salameh T; Zughul R; Alhalaseh Y
J Thromb Thrombolysis; 2023 Oct; 56(3):447-453. PubMed ID: 37430158
[TBL] [Abstract][Full Text] [Related]
11. Comparison between the Khorana prediction score and Caprini risk assessment models for assessing the risk of venous thromboembolism in hospitalized patients with cancer: a retrospective case control study.
Hu Y; Li X; Zhou H; Lin P; Zhang J; Huang D; Qi M; Tang Y; Yi Q; Liang Z; Wang M
Interact Cardiovasc Thorac Surg; 2020 Oct; 31(4):454-460. PubMed ID: 32910201
[TBL] [Abstract][Full Text] [Related]
12. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK).
Kuderer NM; Poniewierski MS; Culakova E; Lyman GH; Khorana AA; Pabinger I; Agnelli G; Liebman HA; Vicaut E; Meyer G; Shepherd FA
Oncologist; 2018 Feb; 23(2):247-255. PubMed ID: 28951500
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification for the development of venous thromboembolism in hospitalized patients with cancer.
Parker A; Peterson E; Lee AYY; de Wit C; Carrier M; Polley G; Tien J; Wu C
J Thromb Haemost; 2018 Jul; 16(7):1321-1326. PubMed ID: 29733498
[TBL] [Abstract][Full Text] [Related]
14. Identification of risk factors for venous thromboembolism and validation of the Khorana score in patients with advanced lung cancer: based on the multicenter, prospective Rising-VTE/NEJ037 study data.
Tsubata Y; Kawakado K; Hamai K; Furuya N; Yokoyama T; Saito R; Nakamura A; Masuda T; Hamaguchi M; Kuyama S; Honda R; Senoo T; Nakanishi M; Hotta T; Yamasaki M; Ishikawa N; Fujitaka K; Kubota T; Kobayashi K; Isobe T
Int J Clin Oncol; 2023 Jan; 28(1):69-78. PubMed ID: 36357710
[TBL] [Abstract][Full Text] [Related]
15. Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer.
Mansfield AS; Tafur AJ; Wang CE; Kourelis TV; Wysokinska EM; Yang P
J Thromb Haemost; 2016 Sep; 14(9):1773-8. PubMed ID: 27273134
[TBL] [Abstract][Full Text] [Related]
16. [Predicting the Incidence of Venous Thromboembolism Using the Khorana Score: A Literature Review].
Nishimura A; Ikeda Y
Yakugaku Zasshi; 2021; 141(4):611-622. PubMed ID: 33790126
[TBL] [Abstract][Full Text] [Related]
17. A modified Khorana score as a risk assessment tool for predicting venous thromboembolism in newly diagnosed advanced lung cancer.
Li S; Gao P; Qiu J; He X; Mao Y
J Thromb Thrombolysis; 2021 Oct; 52(3):898-903. PubMed ID: 33599857
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Khorana Score for Prediction of Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
Iqbal U; Elsayed AS; Ozair S; Jing Z; James G; Li Q; Hussein AA; Guru KA
J Endourol; 2021 Jun; 35(6):821-827. PubMed ID: 33218263
[No Abstract] [Full Text] [Related]
19. Incidence, outcome and risk stratification tools for venous thromboembolism in advanced pancreatic cancer - A retrospective cohort study.
Kruger S; Haas M; Burkl C; Goehring P; Kleespies A; Roeder F; Gallmeier E; Ormanns S; Westphalen CB; Heinemann V; Rank A; Boeck S
Thromb Res; 2017 Sep; 157():9-15. PubMed ID: 28675831
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients.
Rupa-Matysek J; Lembicz M; Rogowska EK; Gil L; Komarnicki M; Batura-Gabryel H
Med Oncol; 2018 Apr; 35(5):63. PubMed ID: 29616356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]